Thanks to private funding, 100% of every dollar donated to The Lustgarten Foundation goes directly to pancreatic cancer research.

Patients Needed for Clinical Trial of Potential New Treatment

Dr. Dung Le, Principal Investigator 
NA_ 00085756

The Lustgarten Foundation is funding efforts related to a clinical trial/research study being led at the Johns Hopkins Kimmel Cancer Center, in connection with one of our Distinguished Scholars, Dr. Bert Vogelstein, and his colleagues Luis Diaz and Dung Le. The clinical trial/research study will test the effectiveness of Merck’s Pembrolizumab* immunotherapy drug in patients whose tumors have a unique mutation. This mutation can only be identified through testing of tumor tissue for a characteristic genetic signature called “MSI” (microsatellite instability), found in approximately 2 percent of pancreatic cancer patients. A recent research study led at Johns Hopkins demonstrated that patients with a variety of advanced cancers whose tumors had this unique genetic signature responded to Pembrolizumab, even when other forms of therapy were not effective. 

Pancreatic cancer patients interested in this clinical trial/research study should speak with their physicians about having their tumors tested for MSI by ProPath. The Lustgarten Foundation has agreed to pay for this testing. Moreover, those patients who test positive and whose disease is resistant to other therapies may be eligible for this clinical trial/research study at Johns Hopkins using Pembrolizumab. Patients will receive tumor testing, treatment and clinical care free of charge. However, patients may incur other costs. The research study/trial may be limited, so patients who test positive for the MSI mutation will be evaluated on a first come, first served basis.

For more information about this clinical trial/research study, please contact The Lustgarten Foundation at 1-866-789-1000 or ProPath's Client Response Center at 800-258-1253.  Learn More.

Please check back for additional updates on our patient recruitment efforts!

*Note: Pembrolizumab is not yet FDA approved for the treatment of MSI pancreatic cancer.

415 Crossways Park Drive, Suite D, Woodbury, NY 11797
Toll Free: 1-866-789-1000 P: 516-737-1550 F: 516-584-6265


2015 website development and design sponsored by Celgene